-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that neladalkib, a lung cancer drug owned by GSK.US (GSK.US), was approved for marketing by the US Food and Drug Administration (FDA), providing new treatment options for patients whose condition is still progressing after receiving ALK targeted treatment, further verifying the strategic value of the British pharmaceutical company's previous acquisition of biotech company Nuvalent.

Zhitongcaijing·11/17/2026 23:33:23
Listen to the news
The Zhitong Finance App learned that neladalkib, a lung cancer drug owned by GSK.US (GSK.US), was approved for marketing by the US Food and Drug Administration (FDA), providing new treatment options for patients whose condition is still progressing after receiving ALK targeted treatment, further verifying the strategic value of the British pharmaceutical company's previous acquisition of biotech company Nuvalent.